ValuEngine lowered shares of Stemline Therapeutics (NASDAQ:STML) from a hold rating to a sell rating in a research note issued to investors on Tuesday.
STML has been the topic of several other reports. BidaskClub downgraded shares of Stemline Therapeutics from a hold rating to a sell rating in a research note on Friday, December 22nd. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the stock a buy rating in a research note on Thursday, December 14th. Finally, Zacks Investment Research upgraded shares of Stemline Therapeutics from a sell rating to a hold rating in a report on Friday, January 5th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $33.75.
Stemline Therapeutics (STML) opened at $16.75 on Tuesday. Stemline Therapeutics has a one year low of $7.30 and a one year high of $18.75. The company has a market cap of $535.98, a price-to-earnings ratio of -6.52 and a beta of -0.07.
Several hedge funds have recently made changes to their positions in the company. MetLife Investment Advisors LLC bought a new stake in shares of Stemline Therapeutics during the 4th quarter valued at $186,000. Lyon Street Capital LLC boosted its holdings in shares of Stemline Therapeutics by 53.1% during the 4th quarter. Lyon Street Capital LLC now owns 829,090 shares of the biopharmaceutical company’s stock valued at $12,934,000 after buying an additional 287,628 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Stemline Therapeutics by 769.8% during the 4th quarter. Millennium Management LLC now owns 290,005 shares of the biopharmaceutical company’s stock valued at $4,524,000 after buying an additional 256,665 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Stemline Therapeutics during the 4th quarter valued at $170,000. Finally, Consonance Capital Management LP boosted its holdings in shares of Stemline Therapeutics by 2,216.9% during the 4th quarter. Consonance Capital Management LP now owns 2,349,792 shares of the biopharmaceutical company’s stock valued at $36,657,000 after buying an additional 2,248,372 shares in the last quarter. Hedge funds and other institutional investors own 52.09% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Stemline Therapeutics (STML) Cut to Sell at ValuEngine” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3260906/stemline-therapeutics-stml-cut-to-sell-at-valuengine.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.